Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling ...

Update on evaluation of cystic fibrosis transmembrane conductance regulator modulator therapies and continued patient access (November 2023) Responding to the National Institute for Health and Care ...